- Conditions
- Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
- Interventions
- Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion
- Biological · Drug · Other
- Lead sponsor
- CatalYm GmbH
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 6
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 972
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pain
- Interventions
- lidocaine-prilocaine cream, Placebo cream
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Obesity, Overweight
- Interventions
- NNC0638-0355, Placebo (NNC0638-0355)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
- Conditions
- Cancer and Chemotherapy Related Anemia
- Interventions
- Injectafer, Normal Saline
- Drug · Other
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 29
- States / cities
- Corona, California • Fountain Valley, California • Riverside, California + 23 more
- Conditions
- Essential Tremor
- Interventions
- Acamprosate, Placebo, Methazolamide
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- West Bloomfield, Michigan
- Conditions
- Tobacco Use Disorder, Smoking
- Interventions
- Ariva Silver Wintergreen, Placebo Wintergreen
- Other
- Lead sponsor
- Star Scientific, Inc
- Industry
- Eligibility
- 23 Years to 72 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Martinsburg, West Virginia
- Conditions
- Papulopustular Rosacea (PPR)
- Interventions
- CD5024, Azelaic acid 15% Gel
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 683 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
- Conditions
- ADHD - Attention Deficit Disorder With Hyperactivity, Irritability, Aggression Childhood
- Interventions
- CNS Stimulant, Placebo, CNS Stimulant open label first phase
- Drug · Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 7 Years to 12 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Postural Tachycardia Syndrome
- Interventions
- Placebo, Modafinil, Propranolol
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Influenza
- Interventions
- cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Fibroid Uterus, Fibroid Tumor, Leiomyoma, Fibromyoma, Leiomyoma, Uterine
- Interventions
- Simvastatin 40mg, Placebo 40 mg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Abdominal Surgery
- Interventions
- Liposomal bupivacaine, Plain bupivacaine, Normal saline
- Drug
- Lead sponsor
- Edward Mascha
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Long COVID, PASC Post Acute Sequelae of COVID 19
- Interventions
- Valacyclovir celecoxib dose 1, Valacyclovir celecoxib dose 2, Placebo
- Drug
- Lead sponsor
- Bateman Horne Center
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Opioid Pain Medication
- Interventions
- Tranexamic acid, Aminocaproic acid, Recombinant Human Thrombin, Lidocaine Hydrochloride with Epinephrine, Bupivacaine Hydrochloride with Epinephrine
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pain
- Interventions
- Intranasal Oxytocin, Placebo (saline)
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 20 Years to 35 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obesity
- Interventions
- Phosphatidylcholine Deoxycholate, Saline
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 25 Years to 70 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Schizophrenia
- Interventions
- LB-102
- Drug
- Lead sponsor
- LB Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 25
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 20 more
- Conditions
- Asthma in Children
- Interventions
- Inulin
- Drug
- Lead sponsor
- Phoenix Children's Hospital
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Female Genital Diseases
- Interventions
- Amitriptyline, Baclofen, Ketoprofen, Ketamine, Loperamide, Gabapentin, placebo
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Obesity
- Interventions
- Behavioral Treatment, Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
- Behavioral · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypnotic Dependence Among Those With Insomnia
- Interventions
- Hypnotic Medication Open-Label Taper, Hypnotic Medication Blinded Taper
- Behavioral
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
- Interventions
- Guanfacine Extended Release, Placebo
- Drug · Other
- Lead sponsor
- Maimonides Medical Center
- Other
- Eligibility
- 6 Years to 35 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
- Interventions
- [18F]FTP PET/CT
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Obesity
- Interventions
- Behavioral Treatment, Placebo, Phentermine 15 MG
- Behavioral · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania